Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · Real-Time Price · USD
11.19
-0.14 (-1.24%)
At close: Mar 30, 2026, 4:00 PM EDT
11.27
+0.08 (0.71%)
After-hours: Mar 30, 2026, 5:02 PM EDT
Trevi Therapeutics Employees
Trevi Therapeutics had 34 employees as of December 31, 2025. The number of employees increased by 8 or 30.77% compared to the previous year.
Employees
34
Change (1Y)
8
Growth (1Y)
30.77%
Revenue / Employee
n/a
Profits / Employee
-$1,257,618
Market Cap
1.44B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 34 | 8 | 30.77% |
| Dec 31, 2024 | 26 | 1 | 4.00% |
| Dec 31, 2023 | 25 | 0 | - |
| Dec 31, 2022 | 25 | 1 | 4.17% |
| Dec 31, 2021 | 24 | 2 | 9.09% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 975 |
| Immunocore Holdings | 524 |
| Vericel | 398 |
| Intellia Therapeutics | 377 |
| Nurix Therapeutics | 317 |
| Nuvation Bio | 298 |
| Maze Therapeutics | 141 |
| Nanobiotix | 103 |
TRVI News
- 12 days ago - Trevi Therapeutics, Inc. (TRVI) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 20 days ago - Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026 - GlobeNewsWire
- 21 days ago - Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough - GlobeNewsWire
- 4 weeks ago - Trevi Therapeutics to Participate in Upcoming March Conferences - GlobeNewsWire
- 5 weeks ago - Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 2 months ago - Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA) - PRNewsWire
- 2 months ago - Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference - PRNewsWire